Clinical significance of preoperative serum vascular endothelial growth factor, interleukin-6, and C-reactive protein level in colorectal cancer

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Kwon, Kyung A ^a   Kim, Sung H ^a   Oh, Sung Y ^a   Lee, Suee ^a   Han, Jin Yeong ^a   Kim, Kyeong H ^a   Goh, Ri Y ^a   Choi, Hong J ^a   Park, Ki J ^a   Roh, Mee S ^a   Kim, Hyo Jin ^a   Kwon, Hyuk Chan ^a   Lee, Jong H ^a  

^a Dong A University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; INTERLEUKIN 6; VASCULOTROPIN; CARCINOEMBRYONIC ANTIGEN; IL6 PROTEIN, HUMAN; TUMOR MARKER; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; COLORECTAL CARCINOMA; COLORECTAL SURGERY; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PREOPERATIVE EVALUATION; PROGNOSIS; PROTEIN BLOOD LEVEL; REFERENCE VALUE; ADENOCARCINOMA; ADOLESCENT; BLOOD; CASE CONTROL STUDY; COLON RESECTION; COLORECTAL TUMOR; ENZYME LINKED IMMUNOSORBENT ASSAY; KAPLAN MEIER METHOD; METABOLISM; METASTASIS; MIDDLE AGED; PATHOLOGY; PHOTOMETRY; PREDICTION AND FORECASTING; PREOPERATIVE PERIOD; PROPORTIONAL HAZARDS MODEL; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; TIME; TREATMENT OUTCOME;

ADENOCARCINOMA; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; C-REACTIVE PROTEIN; CARCINOEMBRYONIC ANTIGEN; CASE-CONTROL STUDIES; COLECTOMY; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INTERLEUKIN-6; KAPLAN-MEIERS ESTIMATE; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM STAGING; NEPHELOMETRY AND TURBIDIMETRY; PREDICTIVE VALUE OF TESTS; PREOPERATIVE PERIOD; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; ROC CURVE; TIME FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A; YOUNG ADULT;

EID: 77952085846     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-203     Document Type: Article

References (40)

1. Giatromanolaki A, Sivridis E, Koukourakis MI. Angiogenesis in colorectal cancer: prognostic and therapeutic implications. Am J Clin Oncol 2006, 29(4):408-417. 10.1097/01.coc.0000221317.56731.4e, 16891872.
2. Won YJ, Sung J, Jung KW, Kong HJ, Park S, Shin HR, Park EC, Ahn YO, Hwang IK, Lee DH, et al. Nationwide cancer incidence in Korea, 2003-2005. Cancer Res Treat 2009, 41(3):122-131. 10.4143/crt.2009.41.3.122, 2757659, 19809561.
3. Compton CC, Greene FL. The staging of colorectal cancer: 2004 and beyond. CA Cancer J Clin 2004, 54(6):295-308. 10.3322/canjclin.54.6.295, 15537574.
4. Folkman J. What is the evidence that tumors are angiogenesis dependent?. J Natl Cancer Inst 1990, 82(1):4-6. 10.1093/jnci/82.1.4, 1688381.
5. Rak J, Filmus J, Finkenzeller G, Grugel S, Marme D, Kerbel RS. Oncogenes as inducers of tumor angiogenesis. Cancer Metastasis Rev 1995, 14(4):263-277. 10.1007/BF00690598, 8821090.
6. Brown LF, Detmar M, Claffey K, Nagy JA, Feng D, Dvorak AM, Dvorak HF. Vascular permeability factor/vascular endothelial growth factor: a multifunctional angiogenic cytokine. EXS 1997, 79:233-269.
7. Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 1995, 146(5):1029-1039. 1869291, 7538264.
8. Reinmuth N, Parikh AA, Ahmad SA, Liu W, Stoeltzing O, Fan F, Takeda A, Akagi M, Ellis LM. Biology of angiogenesis in tumors of the gastrointestinal tract. Microsc Res Tech 2003, 60(2):199-207. 10.1002/jemt.10258, 12539174.
9. Ferrara N. Molecular and biological properties of vascular endothelial growth factor. J Mol Med 1999, 77(7):527-543. 10.1007/s001099900019, 10494799.
10. Takahashi Y, Kitadai Y, Bucana CD, Cleary KR, Ellis LM. Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res 1995, 55(18):3964-3968.
11. Van Snick J. Interleukin-6: an overview. Annu Rev Immunol 1990, 8:253-278. 10.1146/annurev.iy.08.040190.001345, 2188664.
12. Sehgal PB. Regulation of IL6 gene expression. Res Immunol 1992, 143(7):724-734. 10.1016/0923-2494(92)80011-9, 1439145.
13. Cohen T, Nahari D, Cerem LW, Neufeld G, Levi BZ. Interleukin 6 induces the expression of vascular endothelial growth factor. J Biol Chem 1996, 271(2):736-741. 10.1074/jbc.271.2.736, 8557680.
14. Thong-Ngam D, Tangkijvanich P, Lerknimitr R, Mahachai V, Theamboonlers A, Poovorawan Y. Diagnostic role of serum interleukin-18 in gastric cancer patients. World J Gastroenterol 2006, 12(28):4473-4477.
15. Ballou SP, Lozanski G. Induction of inflammatory cytokine release from cultured human monocytes by C-reactive protein. Cytokine 1992, 4(5):361-368. 10.1016/1043-4666(92)90079-7, 1420997.
16. Cermak J, Key NS, Bach RR, Balla J, Jacob HS, Vercellotti GM. C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor. Blood 1993, 82(2):513-520.
17. Law DJ, Olschwang S, Monpezat JP, Lefrancois D, Jagelman D, Petrelli NJ, Thomas G, Feinberg AP. Concerted nonsyntenic allelic loss in human colorectal carcinoma. Science 1988, 241(4868):961-965. 10.1126/science.2841761, 2841761.
18. Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, Nakamura Y, White R, Smits AM, Bos JL. Genetic alterations during colorectal-tumor development. N Engl J Med 1988, 319(9):525-532.
19. Tokunaga T, Oshika Y, Abe Y, Ozeki Y, Sadahiro S, Kijima H, Tsuchida T, Yamazaki H, Ueyama Y, Tamaoki N, et al. Vascular endothelial growth factor (VEGF) mRNA isoform expression pattern is correlated with liver metastasis and poor prognosis in colon cancer. Br J Cancer 1998, 77(6):998-1002. 2150098, 9528847.
20. Ishigami SI, Arii S, Furutani M, Niwano M, Harada T, Mizumoto M, Mori A, Onodera H, Imamura M. Predictive value of vascular endothelial growth factor (VEGF) in metastasis and prognosis of human colorectal cancer. Br J Cancer 1998, 78(10):1379-1384. 2063176, 9823983.
21. Takahashi Y, Tucker SL, Kitadai Y, Koura AN, Bucana CD, Cleary KR, Ellis LM. Vessel counts and expression of vascular endothelial growth factor as prognostic factors in node-negative colon cancer. Arch Surg 1997, 132(5):541-546.
22. Cascinu S, Staccioli MP, Gasparini G, Giordani P, Catalano V, Ghiselli R, Rossi C, Baldelli AM, Graziano F, Saba V, et al. Expression of vascular endothelial growth factor can predict event-free survival in stage II colon cancer. Clin Cancer Res 2000, 6(7):2803-2807.
23. Werther K, Christensen IJ, Brunner N, Nielsen HJ. Soluble vascular endothelial growth factor levels in patients with primary colorectal carcinoma. The Danish RANX05 Colorectal Cancer Study Group. Eur J Surg Oncol 2000, 26(7):657-662. 10.1053/ejso.2000.0977, 11078612.
24. Werther K, Christensen IJ, Nielsen HJ. The association between preoperative concentration of soluble vascular endothelial growth factor, perioperative blood transfusion, and survival in patients with primary colorectal cancer. Eur J Surg 2001, 167(4):287-292. 10.1080/110241501300091480, 11354321.
25. Werther K, Christensen IJ, Nielsen HJ. Prognostic impact of matched preoperative plasma and serum VEGF in patients with primary colorectal carcinoma. Br J Cancer 2002, 86(3):417-423. 10.1038/sj.bjc.6600075, 2375229, 11875709.
26. De Vita F, Orditura M, Lieto E, Infusino S, Morgillo F, Martinelli E, Castellano P, Romano C, Ciardiello F, Catalano G, et al. Elevated perioperative serum vascular endothelial growth factor levels in patients with colon carcinoma. Cancer 2004, 100(2):270-278. 10.1002/cncr.11911, 14716760.
27. Zafirellis K, Agrogiannis G, Zachaki A, Gravani K, Karameris A, Kombouras C. Prognostic significance of VEGF expression evaluated by quantitative immunohistochemical analysis in colorectal cancer. J Surg Res 2008, 147(1):99-107. 10.1016/j.jss.2007.05.041, 17655863.
28. Belluco C, Nitti D, Frantz M, Toppan P, Basso D, Plebani M, Lise M, Jessup JM. Interleukin-6 blood level is associated with circulating carcinoembryonic antigen and prognosis in patients with colorectal cancer. Ann Surg Oncol 2000, 7(2):133-138. 10.1007/s10434-000-0133-7, 10761792.
29. Galizia G, Orditura M, Romano C, Lieto E, Castellano P, Pelosio L, Imperatore V, Catalano G, Pignatelli C, De Vita F. Prognostic significance of circulating IL-10 and IL-6 serum levels in colon cancer patients undergoing surgery. Clin Immunol 2002, 102(2):169-178. 10.1006/clim.2001.5163, 11846459.
30. Nikiteas NI, Tzanakis N, Gazouli M, Rallis G, Daniilidis K, Theodoropoulos G, Kostakis A, Peros G. Serum IL-6, TNFalpha and CRP levels in Greek colorectal cancer patients: prognostic implications. World J Gastroenterol 2005, 11(11):1639-1643.
31. Castell JV, Gomez-Lechon MJ, David M, Hirano T, Kishimoto T, Heinrich PC. Recombinant human interleukin-6 (IL-6/BSF-2/HSF) regulates the synthesis of acute phase proteins in human hepatocytes. FEBS Lett 1988, 232(2):347-350. 10.1016/0014-5793(88)80766-X, 2454206.
32. Crumley AB, McMillan DC, McKernan M, Going JJ, Shearer CJ, Stuart RC. An elevated C-reactive protein concentration, prior to surgery, predicts poor cancer-specific survival in patients undergoing resection for gastro-oesophageal cancer. Br J Cancer 2006, 94(11):1568-1571. 2361311, 16685271.
33. Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 2003, 107(3):363-369. 10.1161/01.CIR.0000053730.47739.3C, 12551853.
34. Trichopoulos D, Psaltopoulou T, Orfanos P, Trichopoulou A, Boffetta P. Plasma C-reactive protein and risk of cancer: a prospective study from Greece. Cancer Epidemiol Biomarkers Prev 2006, 15(2):381-384. 10.1158/1055-9965.EPI-05-0626, 16492932.
35. Krzystek-Korpacka M, Matusiewicz M, Diakowska D, Grabowski K, Blachut K, Kustrzeba-Wojcicka I, Terlecki G, Gamian A. Acute-phase response proteins are related to cachexia and accelerated angiogenesis in gastroesophageal cancers. Clin Chem Lab Med 2008, 46(3):359-364. 10.1515/CCLM.2008.089, 18303990.
36. Zhang SM, Lin J, Cook NR, Lee IM, Manson JE, Buring JE, Ridker PM. C-reactive protein and risk of breast cancer. J Natl Cancer Inst 2007, 99(11):890-894. 10.1093/jnci/djk202, 17551149.
37. Denizot Y, Fixe P, Liozon E, Praloran V. Serum interleukin-8 (IL-8) and IL-6 concentrations in patients with hematologic malignancies. Blood 1996, 87(9):4016-4017.
38. Nozoe T, Matsumata T, Sugimachi K. Preoperative elevation of serum C-reactive protein is related to impaired immunity in patients with colorectal cancer. Am J Clin Oncol 2000, 23(3):263-266.
39. Nozoe T, Matsumata T, Kitamura M, Sugimachi K. Significance of preoperative elevation of serum C-reactive protein as an indicator for prognosis in colorectal cancer. Am J Surg 1998, 176(4):335-338. 10.1016/S0002-9610(98)00204-9, 9817250.
40. McMillan DC, Wotherspoon HA, Fearon KC, Sturgeon C, Cooke TG, McArdle CS. A prospective study of tumor recurrence and the acute-phase response after apparently curative colorectal cancer surgery. Am J Surg 1995, 170(4):319-322. 10.1016/S0002-9610(99)80296-7, 7573721.